Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 328.00
Bid: 325.50
Ask: 330.00
Change: 0.00 (0.00%)
Spread: 4.50 (1.382%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 328.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 recovers 1% on energy, healthcare stock boost; Entain jumps

Tue, 21st Sep 2021 09:14

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Kingfisher top FTSE 100 loser despite positive results

* Royal Dutch Shell sells U.S. oilfield assets

* Stagecoast surges on merger talks with rival

* FTSE 100 up 1.0%, FTSE 250 adds 0.8%
(Updates to close)

By Shashank Nayar

Sept 21 (Reuters) - London's FTSE 100 rebounded on Tuesday,
aided by gains in energy and healthcare stocks, and Entain
jumped to the top of the index after the Ladbrokes owner said it
received an offer from DraftKings.

The blue-chip FTSE 100 ended 1.0% higher and
recorded its best session in two months. Oil major BP and
Royal Dutch Shell were among the top boosts.

Entain jumped 18.0%, leading gains on travel and
leisure stocks, after it confirmed that U.S.
fantasy sports betting company DraftKings has made an
offer to buy the British gambling firm in a deal that one media
report said could be valued at $20 billion.

The FTSE 100 has gained 8% so far this year on support from
dovish central bank policies and re-opening optimism. However,
higher inflation pressures have raised scepticism among
investors that central banks might hint later this week towards
pulling back massive asset purchases sooner than expected.

"Investors are still progressing ahead with fingers crossed
as the Fed and the BoE are unlikely to declare any tapering
measures this time, as it would potentially unsettle the global
equity environment before the third-quarter earnings season,"
said Kunal Sawhney, chief executive at Kalkine.

Healthcare stocks gained 1.5% with drugmakers
including AstraZeneca, Indivior, Oxford
BioMedica up between 1.6% and 4.8%.

The domestically focussed mid-cap index rose 0.8%,
with travel stocks being among the top gainers.

In earnings-driven moves, Kingfisher fell 4.9% to
the bottom of the FTSE 100 even as the British home improvement
retailer reported a jump in first-half profit.

Royal Dutch Shell jumped 3.6% after it said it would sell
its Permian Basin assets to ConocoPhillips for $9.5
billion in cash, exiting the largest U.S. oilfield.

British transport company Stagecoach Group surged
27.0% to the top of mid-cap index, after it said it was in talks
with rival operator National Express about a possible
all-share merger. National Express was up 7.6%.

Semiconductor technology company Alphawave jumped
19.4% on raising its 2021 guidance after reporting a 140% rise
in first-half revenue.
(Reporting by Shashank Nayar and Amal S in Bengaluru; Editing
by Saumyadeb Chakrabarty, Subhranshu Sahu and Marguerita Choy)

More News
8 Apr 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 08:19

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Oxford Biomedica signs viral vectors pact with Boehringer Ingelheim

Read more
6 Apr 2021 08:08

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.

Read more
6 Apr 2021 07:53

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

LONDON MARKET PRE-OPEN: Returns in store for BP shareholders

Read more
21 Mar 2021 20:57

EU rebuffs UK calls to ship AstraZeneca COVID vaccines from Europe

By Francesco GuarascioBRUSSELS, March 21 (Reuters) - The European Union is rebuffing British government calls to ship AstraZeneca COVID-19 vaccines produced in a factory in the Netherlands, an EU official said on Sunday.Former EU member Britain ha...

Read more
19 Mar 2021 10:29

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Sanofi to terminate haemophilia development pact with Oxford Biomedica

Read more
19 Mar 2021 07:50

Oxford Biomedica says Sanofi pulling out of haemophilia project

(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.

Read more
3 Feb 2021 13:56

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

IN BRIEF: Oxford Biomedica Adds Genetics Professor To Non-Exec Team

Read more
29 Jan 2021 09:11

UPDATE 1-EU holds out for more after AstraZeneca offered 8 mln extra COVID-19 shots

* Astra had committed to at least 80 mln shots in Q1* EU funded two UK plants under deal with Astra - sources* Astra says UK has priority for doses produced there (Adds detail, background)By Francesco Guarascio and Sabine SieboldBRUSSELS, Jan 29 (Re...

Read more
18 Jan 2021 17:18

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

IN BRIEF: Oxford Biomedica's Facility In Oxford Now Formally Opened

Read more
8 Jan 2021 09:40

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next

Read more
8 Dec 2020 12:31

UK's initial AstraZeneca shots will come from Europe, taskforce says

By Alistair SmoutLONDON, Dec 8 (Reuters) - Britain's initial doses of the COVID-19 vaccine candidate developed by AstraZeneca and Oxford University will come from Europe rather than a domestic supply chain, the country's Vaccine Taskforce said.The...

Read more
1 Dec 2020 14:29

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

Read more
9 Nov 2020 10:01

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Read more
9 Nov 2020 09:16

Oxford Biomedica strikes collaboration agreement with PhoreMost

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.